Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to ...

ImmunityBio last week won the FDA’s approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine to treat certain patients with bladder cancer. Problem is, ...

ImmunityBio has entered an exclusive worldwide agreement with the Serum Institute of India to secure a supply of Bacillus ...

ImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of Anktiva, its cancer drug.

After years of effort, delays and hundreds of millions of dollars of billionaire Patrick Soon-Shiong’s own money, last week ...

Immunitybio Inc’s IBRX share price has surged by 43.84%, which has investors questioning if this is right time to sell.

The U.S. health regulator on Monday approved ImmunityBio's combination therapy to treat a type of bladder cancer, marking an ...

Today, Benzinga 's options scanner spotted 19 uncommon options trades for ImmunityBio. This isn't normal. The overall ...

ImmunityBio has financial resources for the short-term, but long-term financial health remains uncertain. Click here to read ...

ImmunityBio (NASDAQ: IBRX) stock price resumed its strong rally this week after the company achieved a major milestone. After ...

The Food and Drug Administration on Monday approved Culver City-based ImmunityBio’s treatment for bladder cancer.

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its ...